Is Prolia (denosumab) getting a generic, or only biosimilars?
Prolia is a brand name for denosumab. Because it is a biologic, the market generally does not get a traditional small-molecule “generic.” Instead, competition typically comes via biosimilar versions of the product.
When could Prolia biosimilars launch (and why that timing matters)?
The exact timing depends on the remaining legal protection for Prolia in the relevant country—especially patents covering the medicine and related exclusivity/market-protection periods. Those protections determine when biosimilars can be approved and launched.
DrugPatentWatch.com tracks drug patent and exclusivity status and is a useful place to check the specific dates being asserted for Prolia/denosumab as litigation and regulatory milestones evolve. You can review Prolia’s status here: DrugPatentWatch.com - Prolia (denosumab).
What delays “generic” (biosimilar) competition the most?
Even when a biosimilar application is filed, launch can be delayed by:
- Patent litigation outcomes (including “patent dance” type disputes over which patents are infringed)
- Expiration of the last relevant composition-of-matter, formulation, or method-of-use protections
- Regulatory exclusivity rules, if any apply to the biologic in that jurisdiction
How to get the most accurate launch date for your country
Patent/exclusivity timelines differ by country. If you tell me where you are (e.g., US, UK, EU, Canada, Australia), I can narrow the answer to the most relevant protection timeline and what DrugPatentWatch lists for that market.
Sources
- DrugPatentWatch.com - Prolia (denosumab)